Description of the protocol for the PRACTICAL study: a randomised controlled trial of the efficacy and safety of ICS/LABA reliever therapy in asthma

Introduction In adult asthma, combination inhaled corticosteroid (ICS)/fast-onset long-acting beta agonist (LABA) used solely as reliever therapy may represent an effective and safe alternative to ICS maintenance and short-acting beta agonist (SABA) reliever therapy. Objective To compare the efficacy and safety of ICS/fast-onset LABA reliever therapy with ICS maintenance and SABA reliever therapy in adults with asthma. Methods and analysis A 52-week, open-label, parallel group, multicentre, phase III randomised controlled trial with 1:1 randomisation to either budesonide/formoterol Turbuhaler 200/6 µg, one actuation as required for symptom relief, or budesonide Turbuhaler 200 µg, one actuation twice daily and terbutaline Turbuhaler 250 µg, two actuations as required for symptom relief. 890 adults aged 18–75 years with asthma for whom maintenance ICS and SABA reliever therapy is indicated by current guidelines will be recruited in New Zealand. The primary outcome variable is the rate of severe exacerbations per patient per year. This study will investigate a novel treatment regimen that might lead to a paradigm shift in asthma management for adults for whom guidelines currently recommend maintenance ICS and SABA reliever therapy. Ethics and dissemination Ethical approval has been granted (15/NTB/178). Study findings will be published according to Iinternational Committee of Medical Journal Editors' recommendations. Trial registration number ACTRN12616000377437; Pre-results.

[1]  W. Busse,et al.  Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study , 2017, The Lancet.

[2]  I. Pavord,et al.  Description of a randomised controlled trial of inhaled corticosteroid/fast-onset LABA reliever therapy in mild asthma , 2016, European Respiratory Journal.

[3]  M. Weatherall,et al.  Three-month validation of a turbuhaler electronic monitoring device: implications for asthma clinical trial use , 2015, BMJ Open Respiratory Research.

[4]  Helen K. Reddel,et al.  A summary of the new GINA strategy: a roadmap to asthma control , 2015, European Respiratory Journal.

[5]  D. Shaw,et al.  The use of β2-agonist therapy before hospital attendance for severe asthma exacerbations: a post-hoc analysis , 2015, npj Primary Care Respiratory Medicine.

[6]  M. Weatherall,et al.  Combination budesonide/formoterol inhaler as maintenance and reliever therapy in Māori with asthma , 2014, Respirology.

[7]  D. Postma,et al.  Integrating real-life studies in the global therapeutic research framework. , 2013, The Lancet. Respiratory medicine.

[8]  D. Shaw,et al.  Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. , 2013, The Lancet. Respiratory medicine.

[9]  Bernadette A. Thomas,et al.  Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[10]  D. Shaw,et al.  Use of metered-dose inhaler electronic monitoring in a real-world asthma randomized controlled trial. , 2013, The journal of allergy and clinical immunology. In practice.

[11]  R. Beasley,et al.  Six-month in vitro validation of a metered-dose inhaler electronic monitoring device: implications for asthma clinical trial use. , 2012, Journal of Allergy and Clinical Immunology.

[12]  Tonya S. King,et al.  Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. , 2012, JAMA.

[13]  I. Pavord,et al.  An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. , 2009, American journal of respiratory and critical care medicine.

[14]  I. Adcock,et al.  Rescue treatment in asthma. More than as-needed bronchodilation. , 2009, Chest.

[15]  William W Busse,et al.  Severe exacerbations and decline in lung function in asthma. , 2009, American journal of respiratory and critical care medicine.

[16]  H. Birnbaum,et al.  Costs and Resource Use of Mild Persistent Asthma Patients Initiated on Controller Therapy , 2008, The Journal of asthma : official journal of the Association for the Care of Asthma.

[17]  R. Horne,et al.  Beliefs about medicines predict refill adherence to inhaled corticosteroids. , 2008, Journal of psychosomatic research.

[18]  G. Canonica,et al.  Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. , 2007, The New England journal of medicine.

[19]  Richard Beasley,et al.  An audiovisual reminder function improves adherence with inhaled corticosteroid therapy in asthma. , 2007, The Journal of allergy and clinical immunology.

[20]  P. Barnes,et al.  Scientific rationale for using a single inhaler for asthma control , 2007, European Respiratory Journal.

[21]  G. Rodrigo.  Rapid effects of inhaled corticosteroids in acute asthma: an evidence-based evaluation. , 2006, Chest.

[22]  T. Haahtela,et al.  Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: a SOMA study , 2006, European Respiratory Journal.

[23]  K. Rabe,et al.  Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study , 2006, The Lancet.

[24]  K. Rabe,et al.  Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. , 2006, Chest.

[25]  M. Weatherall,et al.  Inhaled Corticosteroid Therapy in the Management of Asthma in Adults: Leukotriene Modifiers , 2005 .

[26]  Klas Svensson,et al.  Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. , 2005, Respiratory medicine.

[27]  H. Bisgaard,et al.  Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. , 2005, American journal of respiratory and critical care medicine.

[28]  Christine C Johnson,et al.  Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. , 2004, The Journal of allergy and clinical immunology.

[29]  Kevin B Weiss,et al.  Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. , 2004, The Journal of allergy and clinical immunology.

[30]  M. Weatherall,et al.  Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis , 2004, European Respiratory Journal.

[31]  R. Beasley,et al.  The use of the self-management plan system of care in adult asthma. , 2004, Primary care respiratory journal : journal of the General Practice Airways Group.

[32]  P. Gibson,et al.  High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children. , 2003, The Cochrane database of systematic reviews.

[33]  William W Busse,et al.  Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial , 2003, The Lancet.

[34]  A Tattersfield,et al.  Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. , 2001, American journal of respiratory and critical care medicine.

[35]  N. Pearce,et al.  β agonists: What is the evidence that their use increases the risk of asthma morbidity and mortality? , 1999 .

[36]  J. Weinman,et al.  The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication , 1999 .

[37]  N. Pearce,et al.  Beta-agonists: what is the evidence that their use increases the risk of asthma morbidity and mortality? , 1999, The Journal of allergy and clinical immunology.

[38]  R. Dockhorn,et al.  Effects of budesonide by means of the Turbuhaler on the hypothalmic-pituitary-adrenal axis in asthmatic subjects: a dose-response study. , 1998, The Journal of allergy and clinical immunology.